Stibbe advises Lundbeck

Stibbe advises Lundbeck

Stibbe advises Lundbeck

29.03.2018 NL law

Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.

Lundbeck (listed on the Copenhagen Stock Exchange in Denmark) is a global pharmaceutical company specialising in psychiatric and neurological disorders with a focus on Alzheimer's disease, depression, Parkinson's disease and schizophrenia.


Related experience

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring